GLOPID-R Call for Proposals: Accelerating clinical trial site readiness in LMICS

GLOPID-R in coordination with the EDCTP association is calling for porposals on Outbreak ready: Accelerating clinical trial site readiness in LMICS.

The aim of Call 1 is for GloPID-R members to fund projects that strengthen clinical trial sites in low- and middle-income countries (LMICs), supporting the implementation of three of the actions outlined by the World Health Organization’s Global Action Plan for Clinical Trial Ecosystem Strengthening (GAP-CTS): Action 4 (Innovation), Action 6 (Ethics and Regulatory), and Action 9 (Collaboration).

Expected outcomes:

The purpose of this topic is to support existing investments in clinical trial research made by GloPID-R members in LMICs. Proposals should aim to strengthen the clinical trial ecosystem by delivering results that contribute to the following GAP-CTS Actions:

• Action 4: Enable effective trials through adoption of innovative designs and digital technologies
• Action 6: Improve coordination and streamlining of regulatory and ethics review
• Action 9: Expand international health research and clinical trial collaboration

While proposals may add value to ongoing clinical trial initiatives, the expected outcomes must go beyond the support of individual trials and contribute to the strengthening of the clinical trial ecosystem more broadly.

Elegibility: 

To be eligible for funding under this GRIPP call, proposals must adhere to the following requirements:

1. Its content corresponds, wholly or in part, to the call scope description above, supporting at least one of GAP-CTS Action 4, 6 or 9
2. Primary benefit should be focused on the clinical trial ecosystem in LMIC(s)
3. Each proposal must be submitted by a consortium of organizations (minimum 2, maximum 4) including:
   • One organization currently funded by an GloPID-R Member¹ to conduct a clinical trial(s) (phase I-III)² focused on (re-)emerging diseases of epidemic potential.³
     • ¹ The funder does not need to contribute to this call but must be one of the 35 GloPID-R members
     • ² Clinical trial verification must be provided through a funding award letter and trial registration in a WHO-compliant registry
     • ³ Defined as high-priority pathogens outlined in the ‘Pathogens prioritization: a scientific framework for epidemic and pandemic research preparedness’ report
   • At least one organization from an LMIC
   • For proposals under Action 6 (Ethics), the consortium must include at least one legal entity hosting a national regulatory  authority and/or ethics committee in the LMIC concerned.

Financial provisions:

• Projects may request between a minimum of 100,000 EUR and a maximum of 500,000 EUR, inclusive of an acceptable overhead rate based on the overhead policy of the lead administering organization up to a maximum of 8%.
• Maximum duration of supported grants: 24 months

Read here for more information. 

Application deadline, 14th of November 2025.